8-K: Agilon Health Reports Mixed Q4 Results, Focuses on Strategic Adjustments for 2025

Agilon Health's Q4 2024 results show revenue growth but continued losses, prompting strategic actions and a focus on cost discipline for improved 2025 performance.

Summary

• Agilon Health reported a 44% increase in revenue to $1.52 billion for Q4 2024, compared to $1.06 billion in Q4 2023.
• Full year 2024 revenue increased 40% to $6.06 billion from $4.32 billion in 2023.
• Medicare Advantage membership grew 36% year-over-year, reaching 527,000 members.
• The company reported a gross profit of negative $38 million for Q4 2024, an improvement from negative $95 million in Q4 2023.
• However, the full year 2024 gross profit was $5 million, down from $70 million in 2023.
• Net loss for Q4 2024 was $106 million, compared to a net loss of $230 million in Q4 2023.
• The full year 2024 net loss was $260 million, nearly the same as the $263 million loss in 2023.
• Adjusted EBITDA loss for Q4 2024 was $84 million, compared to a loss of $137 million in Q4 2023.
• The full year 2024 Adjusted EBITDA loss was $154 million, compared to a loss of $95 million in 2023.
• For 2025, the company expects to add approximately 20,000 Medicare Advantage members from the Class of 2025.
• The company anticipates total revenues between $5.825 billion and $6.025 billion for fiscal year 2025.
• Medical margin is projected to be between $275 million and $325 million for fiscal year 2025.
• Adjusted EBITDA is expected to be between negative $95 million and negative $55 million for fiscal year 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While revenue growth is positive, continued losses and strategic exits suggest challenges. The company is taking steps to improve, but the outlook remains uncertain.

Positives

• Revenue increased significantly in both Q4 2024 and full year 2024.
• Medicare Advantage membership continues to grow at a substantial rate.
• The company is taking strategic actions to reduce underwriting risks and improve platform capabilities.
• Gross profit and net losses improved in Q4 2024 compared to Q4 2023.
• The company is focused on cost discipline and improving operational efficiency.
• Agilon is implementing clinical and operating programs to improve physician onboarding and clinical expense management.

Negatives

• The company experienced a gross profit loss in Q4 2024 and a significantly reduced gross profit for the full year 2024 compared to the previous year.
• The company reported a net loss for both Q4 2024 and the full year 2024.
• Adjusted EBITDA losses continued in both Q4 2024 and the full year 2024.
• Elevated medical costs continue to negatively impact the company's financial performance.
• The company is exiting some partnerships and contracts, indicating underperformance in those areas.

Risks

• The company is managing through a challenging Medicare Advantage environment.
• Elevated medical cost trends are expected to continue in 2025.
• The Inflation Reduction Act may negatively impact the company's financial results.
• The company's ability to achieve its financial projections depends on the success of its strategic actions and operating initiatives.
• The company faces risks related to healthcare regulations, audits, and investigations.

Future Outlook

Agilon Health anticipates total revenues between $5.825 billion and $6.025 billion, medical margin between $275 million and $325 million, and Adjusted EBITDA between negative $95 million and negative $55 million for fiscal year 2025.

Management Comments

• Steve Sell, CEO, stated that while the underlying strength of the company's model continues to deliver significant value, they are still managing through a challenging Medicare Advantage environment.
• Management believes strategic actions taken to reduce underwriting risks, improve platform capabilities, and maintain cost discipline have established a stronger foundation for success.

Industry Context

Agilon Health operates in the value-based care sector, partnering with physicians to manage the health of senior patients. The company's performance is influenced by trends in Medicare Advantage, including reimbursement rates, medical cost inflation, and regulatory changes such as the Inflation Reduction Act.

Comparison to Industry Standards

• It's difficult to provide a direct comparison without knowing the specific financial details of Agilon's competitors.
• However, companies like Oak Street Health (acquired by CVS Health) and Alignment Healthcare also operate in the Medicare Advantage space and focus on value-based care.
• Investors would typically compare Agilon's membership growth, revenue growth, medical cost ratios, and profitability metrics against these peers to assess its relative performance.
• Agilon's strategic shift to exit underperforming markets and focus on cost discipline is a common strategy in the industry to improve profitability.

Stakeholder Impact

• Shareholders may be concerned about the continued losses and declining profitability metrics.
• Physician partners will be impacted by the company's strategic decisions and operating initiatives.
• Members may experience changes in their healthcare coverage as the company exits certain markets.
• Payors will be affected by the company's contract negotiations and risk management strategies.

Next Steps

• The company will focus on executing its strategic actions to improve underwriting risks and platform capabilities.
• Agilon will continue to manage costs and improve operational efficiency.
• The company will monitor medical cost trends and adapt its strategies accordingly.
• Agilon will provide updates on its progress in future earnings releases and investor communications.

Key Dates